Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

Table 2 Key features and treatment outcomes of each advanced ESCC patient

No.	Age (years)	Gender	ECOG PS	Location	Clinical T stage	Clinical N stage	Clinical TNM stage	Treatment response	TRG	pCR	R0 resection	Progression	PFS (months)	Death	OS (months)
1	57	M	0	Proximal third	T3	N0	Stage II	CR	1	No	Yes	No	16	No	16
2	64	M	0	Proximal third	T2	N1	Stage II	CR	0	Yes	Yes	No	13	No	13
3	61	M	0	Middle third	T3	N1	Stage III	PR	0	Yes	Yes	No	20	No	20
4	65	M	0	Proximal third	T3	N2	Stage III	PR	2	No	Yes	No	18	No	18
5	52	M	0	Distal third	T2	N1	Stage II	SD	1	No	Yes	No	16	No	16
6	68	M	0	Middle third	T3	N1	Stage III	PR	0	Yes	Yes	No	7	No	7
7	70	M	0	Distal third	T3	N0	Stage II	PR	0	Yes	Yes	No	10	No	10
8	58	M	0	Middle third	T3	N1	Stage III	PR	1	No	Yes	No	17	No	17
9	53	M	1	Distal third	T3	N2	Stage III	PR	1	No	Yes	Yes	13	No	16
10	72	F	1	Middle third	T3	N3	Stage IV	SD	3	No	No	Yes	6	Yes	11
11	56	M	1	Middle third	T3	N1	Stage III	CR	1	No	Yes	No	9	No	9
12	46	M	0	Distal third	T3	N1	Stage III	PR	2	No	Yes	No	6	No	6
13	62	M	0	Distal third	T3	N2	Stage III	PR	1	No	Yes	No	12	No	12
14	60	F	0	Middle third	T3	N1	Stage III	CR	0	Yes	Yes	No	15	No	15
15	56	M	0	Middle third	T4	N1	Stage IV	PR	3	No	Yes	No	4	No	4
16	75	M	0	Middle third	T3	N1	Stage III	SD	2	No	Yes	No	16	No	16

ESCC esophageal squamous cell carcinoma, ECOG PS Eastern Cooperative Oncology Group performance status, TRG tumor regression grade, pCR pathologic complete remission, PFS progression-free survival, OS overall survival, M male, F female, CR complete remission, PR partial remission, SD stable disease, PD progressive disease

ISSN: 1477-7819